JPRN-UMIN000019802CompletedPhase 2
A phase 2 clinical trial of personalized peptide vaccination for castration-resistant prostate cancer (CRPC) patients with slight bone marrow suppression - Personalized peptide vaccination for CRPC patients with slight bone marrow suppression
Cancer Vaccine Center, Kurume University School of medicine0 sites35 target enrollmentStarted: November 16, 2015Last updated:
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Sponsor
- Enrollment
- 35
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- Male
Inclusion Criteria
- Not provided
Exclusion Criteria
- •he following patients must be excluded: 1) Patients with severe symptoms (active and severe infectious disease, circulatory disease, respiratory disease, kidney disease, immunodeficiency, disturbance of coagulation). 2)Active double cancer (synchronous double cancer and metachronous double cancer within 5 disease-free years), excluding carcinoma in situ (lesions equal to intraepithelial or intramucosal cancer) judged to have been cured with local treatment. 3) Patients with the past history of severe allergic reactions. 4) Patients who are judged inappropriate for the clinical trial by doctors.
Investigators
Similar Trials
Completed
Phase 2
A phase II clinical trial of personalized peptide vaccination in combination with metformin for castration-resistant prostate cancer (CRPC)Castration-resistant prostate cancerJPRN-UMIN000019879Cancer Vaccine Center, Kurume University School of medicine35
Completed
Phase 2
Phase II clinical trial of personalized peptide vaccination for gastric cancer patientsgastric cancerJPRN-UMIN000002985Kurume University Cancer Vaccine Center100
Completed
Phase 2
Phase II clinical trial of personalized peptide vaccination in patients with advanced/metastatic urotherial cancer previously treated with M-VAC chemotherapyrotherial cancerJPRN-UMIN000001061Kurume University School of medicine, Department of Immunology20
Completed
Phase 2
Phase II clinical trial of personalized peptide vaccination for urotherial cancer patientsrotherial cancerJPRN-UMIN000003059Kurume University Cancer Vaccine Center100
Completed
Phase 2
Phase II clinical trial of personalized peptide vaccination for Renal cell carcinoma patientsRenal cell carcinomaJPRN-UMIN000003027Kurume University Cancer Vaccine Center100